Truist lowered the firm’s price target on Boston Scientific (BSX) to $95 from $120 but keeps a Buy rating on the shares. The post-earnings move looks overdone, now trading at a discount to higher growth peers, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $115 from $130 at RBC Capital
- Boston Scientific price target lowered to $97 from $121 at Needham
- Boston Scientific price target lowered to $105 from $120 at BofA
- Boston Scientific price target lowered to $115 from $140 at Mizuho
- Boston Scientific price target lowered to $96 from $112 at Evercore ISI